Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14727880rdf:typepubmed:Citationlld:pubmed
pubmed-article:14727880lifeskim:mentionsumls-concept:C0042232lld:lifeskim
pubmed-article:14727880lifeskim:mentionsumls-concept:C1522570lld:lifeskim
pubmed-article:14727880lifeskim:mentionsumls-concept:C2364326lld:lifeskim
pubmed-article:14727880lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:14727880lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:14727880pubmed:issue2lld:pubmed
pubmed-article:14727880pubmed:dateCreated2004-1-19lld:pubmed
pubmed-article:14727880pubmed:abstractTextIn a systematic effort to develop a dual-function intravaginal spermicide as well as a drug delivery vehicle against sexually transmitted pathogens, a submicron particle size (30-80 nm), lipophilic and spermicidal gel-microemulsion (viz GM-144) containing the pharmaceutical excipients propylene glycol, Captex 300, Cremophor EL, Phospholipon 90G, Rhodigel, Pluronic F-68, and sodium benzoate was formulated. GM-144 completely immobilized sperm in human or rabbit semen in less than 30 seconds. Therefore, the in vivo contraceptive potency of intravaginally applied GM-144 was compared in the standard rabbit model to those of the detergent spermicide, nonoxynol-9 (N-9)-containing formulation. Eighty-four ovulated New Zealand White rabbits in subgroups of 28 were artificially inseminated with and without intravaginal administration of GM-144 or 2% N-9 (Gynol II) formulation and allowed to complete term pregnancy. GM-144 showed remarkable contraceptive activity in the rigorous rabbit model. When compared with control, intravaginal administration of GM-144 and Gynol II resulted in 75% and 70.8% inhibition of fertility (P <.0001 versus control, Fisher's exact test), respectively. Thus, GM-144 as a vaginal contraceptive was as effective as the commercially available N-9 gel. In the rabbit vaginal irritation test, none of the 6 rabbits given daily intravaginal application of spermicidal GM-144 for 10 days developed epithelial ulceration, edema, leukocyte influx, or vascular congestion characteristic of inflammation (total score = 5). Therefore, GM-144 has the potential to become a clinically useful safe vaginal contraceptive and a vehicle for formulating lipophilic drugs used in reducing the risk of heterosexual transmission of sexually transmitted diseases.lld:pubmed
pubmed-article:14727880pubmed:languageenglld:pubmed
pubmed-article:14727880pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:citationSubsetIMlld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14727880pubmed:statusMEDLINElld:pubmed
pubmed-article:14727880pubmed:issn1530-9932lld:pubmed
pubmed-article:14727880pubmed:authorpubmed-author:UckunF MFMlld:pubmed
pubmed-article:14727880pubmed:authorpubmed-author:D'CruzO JOJlld:pubmed
pubmed-article:14727880pubmed:authorpubmed-author:YivS HSHlld:pubmed
pubmed-article:14727880pubmed:issnTypeElectroniclld:pubmed
pubmed-article:14727880pubmed:volume2lld:pubmed
pubmed-article:14727880pubmed:ownerNLMlld:pubmed
pubmed-article:14727880pubmed:authorsCompleteYlld:pubmed
pubmed-article:14727880pubmed:paginationE5lld:pubmed
pubmed-article:14727880pubmed:dateRevised2010-11-9lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:meshHeadingpubmed-meshheading:14727880...lld:pubmed
pubmed-article:14727880pubmed:year2001lld:pubmed
pubmed-article:14727880pubmed:articleTitleGM-144, a novel lipophilic vaginal contraceptive gel-microemulsion.lld:pubmed
pubmed-article:14727880pubmed:affiliationDepartment of Reproductive Biology, Drug Discovery Program, Parker Hughes Institute, St Paul, MN, USA. odcruz@ih.orglld:pubmed
pubmed-article:14727880pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14727880pubmed:publicationTypeComparative Studylld:pubmed